Relevium Signs Exclusivity Agreement With SOSCannabis.com for Reimbursement for Pediatric Patients
July 10 2019 - 8:30AM
Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and
Frankfurt: “6BX”) (the “Company” or “Relevium”), announced today it
has executed an exclusivity agreement to partner with SOS cannabis
Inc. (“SOSCannabis”), which will provide pediatric customers with
the ability to obtain free legal representation to seek
reimbursement for the costs of medical cannabinoid therapy from
different government agencies for the treatment of medical
conditions for pediatric patients.
The partnership agreement will provide
Relevium’s pediatric customers with access to an experienced legal
and case management team, who will prepare the case file and seek
retroactive and prospective reimbursement for parents of pediatric
patients at no cost. The agreement provides Relevium with a unique
advantage in terms of its business development strategy and first
to market positioning in terms of pediatric applications.
Mr. Aurelio Useche, CEO of Relevium stated: “As
we prepare to enter the pediatric endo-medicinal market in Canada
with an initial ten (10) CannaKids® formulated products, not only
are we providing parents with a natural alternative and/or health
support mechanism, but now we are able to provide them with the
ability to seek reimbursement from governmental agencies without
any costs,” Mr. Useche stated further: “We are extremely happy to
work with a team of caring legal professionals that can represent
our customers in minimizing the financial burden of cannabinoid
therapy.”
Maitre Robert Astell, President of
SOSCannabis.com stated “We are delighted to welcome Relevium into
our family of medicinal cannabinoid therapy suppliers. The focus
and quest of Relevium in terms of pediatric patients is admirable
and we look forward to onboarding parents into our fully-automated
registration platform and to provide them with the state-of-the-art
case management service in fulfilling their need for economic
assistance in providing natural medicine to their children.”
Tracy Ryan, CEO of Cannakids® stated: “For years
patients have struggled with the high expenses that come along with
using cannabis as a medicine. Especially parents to sick children
who often lose their jobs due to countless hospital stays and
doctor’s appointments. This new opportunity for families is a major
step in the right direction. We are elated that more will now have
the opportunity to afford this powerful, non-toxic option that we
have seen bring unimaginable relief to patients on a global
scale.”
About S.O.S
CannabisSOSCannabis.com is a multi-disciplinary law firm
headquartered in Québec, Canada whose objective is to help people
that use medical cannabis prescribed by a doctor to seek
retroactive and prospective monetary reimbursement through claims
made to governmental organizations. SOS Cannabis also provides
referral services to a network of medical professionals and medical
cannabis suppliers. The company counts with an experienced legal
and administrative team to support medical claims with the
provincial and federal governments.
About Cannakids® CannaKids.org
is a privately held company that has provided CO2 extracted, lab
tested cannabis oil products to thousands of patients over the past
4 years. Using nurse guided assistance, the brand has been
synonymous with some of the most recognized patient success stories
in the world.
About Relevium
TechnologiesRelevium is a publicly-traded company that
operates in the health and wellness industry, including legal
cannabis, with a primary focus on online distribution. The
principal business of the Company is the identification,
evaluation, acquisition and operation of brands and businesses in
the health and wellness markets and medical cannabis. The Company
pursues its business strategy through an acquisition and
partnership model in a holistic approach to encompass a wide range
of health and wellness consumer products. Relevium operates through
two wholly owned subsidiaries:
BGX E-Health LLC (BGX), based in Orlando,
Florida, markets dietary supplements, nutraceuticals, sports
nutrition and cosmeceuticals primarily through its Bioganix® brand
portfolio in the US and Europe. Relevium’s premium brands are sold
at some of the world’s largest retailers including Walmart.com and
Amazon.com.
Biocannabix Health Corporation (BCX), based in
Montreal, Quebec, is a biopharma nutraceutical company focused on
delivering pediatric endo-medicinal nutraceuticals for cannabinoid
therapy.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in policies
of the TSX Venture Exchange) accepts responsibility for the
adequacy or accuracy of this release.
Cautionary Note Regarding
Forward-Looking StatementsThis release includes
certain statements and information that may constitute
forward-looking information within the meaning of applicable
Canadian and United States securities laws. All statements in this
news release, other than statements of historical facts, including
statements regarding future estimates, plans, objectives,
assumptions or expectations of future performance, are
forward-looking statements and contain forward-looking information.
Generally, forward- looking statements and information can be
identified by the use of forward-looking terminology such as
"intends" or "anticipates", or variations of such words and phrases
or statements that certain actions, events or results "may",
"could", "should", or "would" occur. Forward-looking statements are
based on certain material assumptions and analysis made by the
Company and the opinions and estimates of management as of the date
of this press release. These forward-looking statements are subject
to known and unknown risks, uncertainties and other factors that
may cause the actual results, level of activity, performance or
achievements of the Company to be materially different from those
expressed or implied by such forward-looking statements or
forward-looking information.
Although management of the Company has attempted
to identify important factors that could cause actual results to
differ materially from those contained in forward-looking
statements or forward-looking information, there may be other
factors that cause results not to be as anticipated, estimated or
intended. There can be no assurance that such statements will prove
to be accurate, as actual results and future events could differ
materially from those anticipated in such statements. Accordingly,
readers should not place undue reliance on forward- looking
statements and forward-looking information. Readers are cautioned
that reliance on such information may not be appropriate for other
purposes. The Company does not undertake to update any
forward-looking statement, forward-looking information or financial
outlook that are incorporated by reference herein, except in
accordance with applicable securities laws. We seek to rely on the
applicable safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES
INC.
Aurelio UsechePresident and CEO
For more information about this press release: Tel:
+1.888.528.8687Email: investors@releviumcorp.com Website:
www.releviumtechnologies.com
https://www.facebook.com/releviumcorp/https://ca.linkedin.com/company/relevium-technologies-inc-https://twitter.com/releviumcorp?lang=en
Relevium Technologies (TSXV:RLV)
Historical Stock Chart
From Jun 2024 to Jul 2024
Relevium Technologies (TSXV:RLV)
Historical Stock Chart
From Jul 2023 to Jul 2024